Sugi Predict

Sugi Predict / Compounds / Uplarafenib

Uplarafenib

Uplarafenib

SCHEMBL14716189

CCCS(=O)(=O)Nc1cc(F)c(F)c(C(=O)c2ccc3ncc(N4CCOCC4)nc3c2)c1F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 9/20 0.51
▸ PIK3CA P42336 2/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ MTOR P42345 1/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ PRKDC P78527 1/20 0.43
▸ PIK3C3 Q8NEB9 1/20 0.43
▸ CYP2C19 P33261 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CDK6 Q00534 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ HPGD P15428 1/20 0.39
▸ BMPR1B O00238 1/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ PIR O00625 1/20 0.39
▸ AURKA O14965 1/20 0.39
▸ DCLK1 O15075 1/20 0.39
▸ EPHB6 O15197 1/20 0.39
▸ RIPK2 O43353 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uplarafenib SCHEMBL29623930 1.00 BRAF (0.51) BRAFPIK3CAPIK3CDPIK3CBMTOR
SCHEMBL14716024 0.93 BRAF (0.48) BRAFPIK3CAPIK3CDPIK3CBMTOR
SCHEMBL14715927 0.92 BRAF (0.59) BRAFCYP2C19CYP2C9CYP3A4BMPR1B
SCHEMBL14716326 0.90 BRAF (0.48) BRAFPIK3CDPIK3CBMTORPIK3CG
SCHEMBL16506281 0.89 BRAF (0.52) BRAFPIK3CAPIK3CDPIK3CBMTOR
SCHEMBL14715961 0.88 BRAF (0.42) BRAFCYP2C19CYP2C9CYP3A4
SCHEMBL17046454 0.88 BRAF (0.47) BRAFPIK3CACYP2C19CYP2C9CYP3A4
SCHEMBL14716305 0.88 BRAF (0.46) BRAFPIK3CAPIK3CDPIK3CBMTOR
SCHEMBL14716140 0.87 BRAF (0.52) BRAFPIK3CAPIK3CDPIK3CBMTOR
SCHEMBL14716129 0.87 PIK3CB (0.44) BRAFPIK3CAPIK3CDPIK3CBMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116880-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC 2024-04-11 — — US claimed
CN-116887833-A Certain chemical entities, compositions and methods 润新生物公司 2023-10-13 — — CN claimed
EP-4255434-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Neupharma, Inc. (US) 2023-10-11 — — EP claimed
WO-2022119905-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC (US) 2022-06-09 — — WO claimed
US-20200390763-A1 BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER NEUPHARMA, INC. 2020-12-17 — — US claimed
US-10561652-B2 Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer NEUPHARMA, INC. (US) 2020-02-18 — — US claimed
EP-2747767-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA INC (US) 2019-02-20 — — EP claimed
US-9295671-B2 Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer NEUPHARMA, INC. (US) 2016-03-29 — — US claimed
US-20130053384-A1 Certain Chemical Entities, Compositions, and Methods NEUPHARMA, INC. (US) 2013-02-28 — — US claimed
US-20240116880-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC 2024-04-11 — — US disclosed
CN-116887833-A Certain chemical entities, compositions and methods 润新生物公司 2023-10-13 — — CN disclosed
EP-4255434-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Neupharma, Inc. (US) 2023-10-11 — — EP disclosed
WO-2022119905-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC (US) 2022-06-09 — — WO disclosed
WO-2022119905-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC (US) 2022-06-09 — — WO disclosed
EP-2747767-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Neupharma, Inc. (US) 2014-07-02 — — EP disclosed
WO-2013032951-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2013-03-07 — — WO disclosed
WO-2013032951-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2013-03-07 — — WO disclosed
US-20130053384-A1 Certain Chemical Entities, Compositions, and Methods NEUPHARMA, INC. (US) 2013-02-28 — — US disclosed
US-20130053384-A1 Certain Chemical Entities, Compositions, and Methods NEUPHARMA, INC. (US) 2013-02-28 — — US disclosed
US-20130053384-A1 Certain Chemical Entities, Compositions, and Methods NEUPHARMA, INC. (US) 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116880-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, RB1 BRAF 75/4885PIK3CA 87/4885PIK3CD 953/4885
US-20200390763-A1 BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER PDXK, BRAF, CHEK1 BRAF 2/4885PIK3CA 78/4885PIK3CD 319/4885
US-10561652-B2 Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer PDXK, BRAF, CHEK1 BRAF 2/4885PIK3CA 78/4885PIK3CD 319/4885
US-20130053384-A1 Certain Chemical Entities, Compositions, and Methods BRAF, PIK3CA, PLK1 BRAF 1/4885PIK3CA 2/4885PIK3CD 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.